April 2009
Volume 50, Issue 13
ARVO Annual Meeting Abstract  |   April 2009
Effect of Intravitreal Bevacizumab on Macular Edema Secondary to Retinal Vein Occlusions
Author Affiliations & Notes
  • M. K. George
    Ophthalmology, Yale-New Haven Hospital, Yale University, New Haven, Connecticut
  • R. A. Adelman
    Ophthalmology, Yale-New Haven Hospital, Yale University, New Haven, Connecticut
  • Footnotes
    Commercial Relationships  M.K. George, None; R.A. Adelman, None.
  • Footnotes
    Support  Leir Foundation, Newman's Own, RPB
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 5405. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. K. George, R. A. Adelman; Effect of Intravitreal Bevacizumab on Macular Edema Secondary to Retinal Vein Occlusions. Invest. Ophthalmol. Vis. Sci. 2009;50(13):5405.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To evaluate the effect of Bevacizumab on macular edema secondary to central and branch retinal vein occlusions.

Methods: : Retrospective study of 19 patients with macular edema secondary to retinal vein occlusions. Patients were evaluated at baseline using Optical Coherence Tomography (OCT) and Fluorescein Angiography (FA) and given 3 consecutive intravitreal injections of Bevacizumab every 4-6 weeks and followed clinically and using OCT. Further injections were administered on follow up visits if persistent edema was noted. Patients who received any other concurrent treatment modality were excluded from the study. OCTs were evaluated for edema and intraretinal cysts and graded from 0-4 by a masked examiner. Primary end points included visual acuity, central macular thickness (CMT), grade of cyst and edema after one injection, three injections and at the end of follow up. Statistical analyses were done with paired T-tests and ANOVA using SPSS 13.0

Results: : A total of 19 patients (mean age 60) were followed for an average of 9 months. There was -0.21 (p=0.025), -0.29 (p=0.000) and -0.35 (p=0.018) improvement in logMAR visual acuity seen after the first and third injections and at the end of follow up respectively. There was a significant reduction of mean CMT from a baseline of 455µ to 274µ (p=0.000) after the first injection, to 305µ (p=0.015) following three injections and to 231µ (p=0.024) at the end of follow up. We also noted a statistically significant reduction in intraretinal cyst grading (one injection 1.3; p=0.000; three injections 1.5; p=0.004; end of follow up 1.7; p=0.026) and edema grading at all end points (one injection 1.6; p=0.000; three injections 1.5; p=0.006; end of follow up 1.9; p=0.003). The initial grade of macular edema was not significantly associated with the final visual acuity or edema at the end of follow up.

Conclusions: : Intravitreal injection of Bevacizumab leads to clinically significant reduction in macular edema and intraretinal cysts as well as improvement in visual acuity upto 9 months. Benefits from the intervention begins with the first injection and persists with subsequent injections.

Keywords: edema • vascular endothelial growth factor 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.